Konakion Mm Paediatric Ampoules (Phytomenadione)

Phytomenadione serves as a cofactor for the gamma‑carboxylation of specific glutamic acid residues on clotting factors II, VII, IX and X. This biochemical step is essential for producing functional clotting proteins in the liver, thereby restoring normal coagulation and preventing hemorrhage.

The exact dose of Konakion Mm Paediatric Ampoules is determined by the prescribing clinician based on the patient’s age, weight, clinical condition, and route of administration. Healthcare professionals should follow local guidelines and individual patient needs when prescribing.

Safety data for phytomenadione during pregnancy and lactation are limited. The drug should only be used when the potential benefit to the mother or infant outweighs any possible risk. Clinicians should assess each case individually and discuss any concerns with the patient.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide. After submission, the sales team will verify trade or institutional credentials, then provide pricing, availability, shipping details (including cold‑chain handling if needed) and any required import documentation.

Konakion Mm Paediatric Ampoules provides phytomenadione in a sterile injectable form, which offers rapid bioavailability compared with oral vitamin K preparations. This can be advantageous in emergency reversal of anticoagulation or in newborn prophylaxis where immediate effect is desired. Other vitamin K products may be oral or have different excipients, influencing stability and administration routes.

The ampoules should be stored at 2‑8 °C, protected from light, and must not be frozen or shaken. Keep them in the original packaging until use to maintain sterility and potency. If temperature excursions occur, discard the product according to local regulations.

Konakion Mm Paediatric Ampoules can be given by intramuscular, intravenous, or oral routes, depending on the clinical indication and patient condition. Administration should be performed by qualified healthcare personnel following aseptic technique and appropriate dosing guidelines.

Serious adverse reactions, though rare, include anaphylaxis, severe hypotension, hemolysis, and thrombocytopenia. Immediate medical attention is required if any signs of a severe allergic reaction or unexpected bleeding abnormalities occur after administration.

Patients with a known hypersensitivity to phytomenadione or any component of the formulation should avoid using the product. Additionally, it should be used with caution in individuals with a history of severe allergic reactions, and it is contraindicated in newborns with certain metabolic disorders unless specifically advised by a specialist.